Search for Terms or Answers
The NEJM has published the results of the ACCT-2 Study, a double-blind, randomized, placebo-controlled trial evaluating baricitinib, an inhibitor of Janus kinase 1 (JAK1) and JAK2, plus remdesivir in hospitalized adults with Covid-19. The primary outcome was the time to recovery.
Analysis of the NHANES population survey data shows weight gain during adulthood increases the risk of gout and that maintaining normal weight could reduce the overall gout risk by nearly 33%.
The addition of an immunomodulating agent to pegloticase (Krystexxa) among patients with uncontrolled gout significantly improved response rates, a systematic literature review found.
The pendulum and jury are wavering with regard to the benefits of interleukin-6 receptor antagonists in COVID-19; the current NEJM reports the results of a study favoring such biologic therapy in in critically ill COVID-19 patients.
Katz, Arant and Loeser have published a comprehensive open-read overview of osteoarthritis (OA) of the hip and knee in JAMA; underscoring the impact, advances, disappointments and guidelines put forth.
Arthritis & Rheumatology has published the results of a subanalysis from tocilizumab (TCZ) clinical trials showing that Il-6 inhibition was associated with preservation of lung function patients with early systemic sclerosis (SSc).
The NEJM has reported the results of a study showing that avacopan, a C5a receptor inhibitor, is as effective as steroids at treating patients with antineutrophil cytoplasmic antibody (ANCA)–associated vasculitis (AAV).
By downloading this material, I acknowledge that it may be used only for personal use and personal education and that I will accredit RheumNow.com as the source and owner of this material. Commercial use or mass reproduction of this material without permission from RheumNow (info@rheumnow.com) is prohibited.
